Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.
DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.
The ability of cancer cells to change and adapt poses a critical challenge to identifying curative solutions. Tumor evolution has been extensively studied from a genetic perspective, to guide clinicians in selecting the most appropriate therapeutic option based on a patient's mutational profile. However, several studies reported that tumors can evolve toward more aggressive stages or become resistant to therapies without changing their genetic makeup. Indeed, several cell-intrinsic and cell-extrinsic mechanisms contribute to tumor evolution. In this viewpoint, I focus on how chromatin, epigenetic, and transcriptional changes contribute to tumor evolution, allowing cancer cells to transition to different cell states and bypass response to therapies. Although tumor nongenetic evolution is harder to trace and predict, understanding its principles might open new therapeutic opportunities.
Jörg Hülsken, Pablo Hernandez Lopez
Didier Trono, Priscilla Turelli, Evaristo José Planet Letschert, Julien Léonard Duc, Sandra Eloise Kjeldsen, Filipe Amândio Brandão Sanches Vong Martins, Charlène Mireille Raymonde Raclot, Cyril David Son-Tuyên Pulver, Olga Marie Louise Rosspopoff, Romain Forey
Douglas Hanahan, Mélanie Louise Tichet, Elizabeth Anne Allen, Ke Cheng